NASDAQ:MDVL MedAvail (MDVL) Stock Forecast, Price & News $0.28 +0.04 (+16.67%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$0.24▼$0.3250-Day Range$0.17▼$0.3352-Week Range$0.10▼$1.82Volume258,882 shsAverage Volume75,908 shsMarket Capitalization$22.54 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MedAvail MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside971.8% Upside$3.00 Price TargetShort InterestHealthy0.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$32,725 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.30) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.48 out of 5 starsMedical Sector1775th out of 1,980 stocksDrug Stores & Proprietary Stores Industry7th out of 12 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, MedAvail has a forecasted upside of 971.8% from its current price of $0.28.Amount of Analyst CoverageMedAvail has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.35% of the outstanding shares of MedAvail have been sold short.Short Interest Ratio / Days to CoverMedAvail has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MedAvail has recently increased by 31.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedAvail does not currently pay a dividend.Dividend GrowthMedAvail does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDVL. Previous Next 0.6 News and Social Media Coverage News SentimentMedAvail has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MedAvail insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,725.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of MedAvail is held by insiders.Percentage Held by Institutions86.77% of the stock of MedAvail is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MedAvail are expected to grow in the coming year, from ($0.30) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MedAvail is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MedAvail is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedAvail has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MedAvail (NASDAQ:MDVL) StockMedAvail Holdings, Inc. is a pharmacy technology and services company, which engages in the development and commercialization of a self-service pharmacy, mobile application, and kiosk. It operates through the Retail Pharmacy Services and Pharmacy Technology segments. The Retail Pharmacy Services segment includes MedAvail Pharmacy Inc. and does business under the trade name SpotRx Pharmacy. The Pharmacy Technology segment represents MedAvail Technologies Inc. that sells the system including MedCenter prescription dispensing kiosk, software, integration, and maintenance services. The company was founded on April 11, 2007 and is headquartered in Phoenix, AZ.Read More Receive MDVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MedAvail and its competitors with MarketBeat's FREE daily newsletter. Email Address MDVL Stock News HeadlinesMay 19, 2023 | finanznachrichten.deMedAvail Holdings, Inc.: MedAvail Reports First Quarter 2023 Financial ResultsMay 18, 2023 | msn.comMedAvail Holdings GAAP EPS of -$0.16, revenue of $0.62MJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 18, 2023 | msn.comMedAvail Holdings: Q1 Earnings InsightsMay 18, 2023 | finance.yahoo.comMedAvail Reports First Quarter 2023 Financial ResultsMay 18, 2023 | finance.yahoo.comMedAvail to Report First Quarter 2023 Financial Results on May 18May 15, 2023 | finance.yahoo.comMedAvail to Report First Quarter 2023 Financial Results on May 15May 15, 2023 | finance.yahoo.comMedAvail Postpones Reporting of First Quarter 2023 Financial ResultsJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 10, 2023 | marketwatch.com8-K: MedAvail Holdings, Inc.April 15, 2023 | finanznachrichten.deMedAvail Holdings, Inc.: MedAvail Reports Fourth Quarter and Full-Year 2022 Financial ResultsApril 13, 2023 | finance.yahoo.comMedAvail Reports Fourth Quarter and Full-Year 2022 Financial ResultsApril 12, 2023 | finance.yahoo.comMedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on April 13March 30, 2023 | finance.yahoo.comMedAvail Postpones Reporting of Fourth Quarter and FY 2022 Financial ResultsMarch 29, 2023 | benzinga.comMedAvail Holdings's Earnings: A PreviewMarch 29, 2023 | markets.businessinsider.comWhat Wall Street expects from MedAvail's earningsMarch 29, 2023 | americanbankingnews.comMedAvail (MDVL) Scheduled to Post Earnings on ThursdayMarch 16, 2023 | finance.yahoo.comMedAvail to Report Fourth Quarter and Full Year 2022 Financial Results on March 30March 14, 2023 | finance.yahoo.comMedAvail Announces Closing of $16 Million Private PlacementJanuary 26, 2023 | finance.yahoo.comMedAvail announces Sale of Pharmacy Assets to CVS PharmacyJanuary 19, 2023 | finance.yahoo.comMedAvail announces Strategic Restructuring of Business to Focus on ProfitabilityNovember 17, 2022 | finance.yahoo.comMedAvail Ranked in the Top 500 Fastest-Growing Companies in North AmericaNovember 10, 2022 | finance.yahoo.comMedAvail Reports Third Quarter 2022 Financial ResultsOctober 27, 2022 | finance.yahoo.comMedAvail To Report 2022 Third Quarter Financial Results on November 10, 2022October 26, 2022 | finance.yahoo.comMedAvail Announces Technology Partnership with Progressive Care, IncOctober 19, 2022 | globenewswire.comPharmacy Automation Market Growing at Remarkable Growth of 9.88 Billion by 2029, Key Drivers, Size, Share, Demand and Opportunity Analysis - GlobeNewswireOctober 11, 2022 | seekingalpha.comMDVL MedAvail Holdings, Inc.See More Headlines MDVL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDVL Company Calendar Last Earnings11/08/2021Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Drug stores & proprietary stores Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDVL CUSIPN/A CIK1402479 Webwww.medavail.com Phone(905) 812-0023Fax973-348-5707Employees287Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+971.8%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,620,000.00 Net Margins-150.00% Pretax Margin-157.41% Return on Equity-211.71% Return on Assets-109.96% Debt Debt-to-Equity Ratio0.34 Current Ratio6.34 Quick Ratio4.64 Sales & Book Value Annual Sales$43.11 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book5.60Miscellaneous Outstanding Shares80,520,000Free Float77,545,000Market Cap$22.54 million OptionableNot Optionable Beta0.38 Key ExecutivesMark DoerrPresident, Chief Executive Officer & DirectorRamona SeabaughChief Financial OfficerDavid John RawlinsChief Commercial OfficerBob McCluneSenior Vice President-Data & AnalyticsWill MisloskiChief Marketing OfficerKey CompetitorsAthersysNASDAQ:ATHXSientraNASDAQ:SIENLucy Scientific DiscoveryNASDAQ:LSDIMoleculin BiotechNASDAQ:MBRXEdesa BiotechNASDAQ:EDSAView All CompetitorsInsidersRamona SeabaughSold 3,287 sharesTotal: $1,018.97 ($0.31/share)Mark Edward DoerrSold 72,785 sharesTotal: $22,563.35 ($0.31/share)Mark Edward DoerrSold 20,773 sharesTotal: $6,855.09 ($0.33/share)Ramona SeabaughSold 6,727 sharesTotal: $2,287.18 ($0.34/share)View All Insider Transactions MDVL Stock - Frequently Asked Questions What is MedAvail's stock price forecast for 2023? 0 brokers have issued 12 month target prices for MedAvail's stock. Their MDVL share price forecasts range from $1.00 to $5.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 971.8% from the stock's current price. View analysts price targets for MDVL or view top-rated stocks among Wall Street analysts. How have MDVL shares performed in 2023? MedAvail's stock was trading at $0.2998 on January 1st, 2023. Since then, MDVL shares have decreased by 6.6% and is now trading at $0.2799. View the best growth stocks for 2023 here. Are investors shorting MedAvail? MedAvail saw a increase in short interest in May. As of May 15th, there was short interest totaling 283,300 shares, an increase of 31.0% from the April 30th total of 216,200 shares. Based on an average trading volume of 111,500 shares, the short-interest ratio is currently 2.5 days. View MedAvail's Short Interest. When is MedAvail's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our MDVL earnings forecast. How were MedAvail's earnings last quarter? MedAvail Holdings, Inc. (NASDAQ:MDVL) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.02. The company earned $5.79 million during the quarter. MedAvail had a negative net margin of 150.00% and a negative trailing twelve-month return on equity of 211.71%. During the same period in the prior year, the business posted ($0.84) earnings per share. What is MedAvail's stock symbol? MedAvail trades on the NASDAQ under the ticker symbol "MDVL." How do I buy shares of MedAvail? Shares of MDVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MedAvail's stock price today? One share of MDVL stock can currently be purchased for approximately $0.28. How much money does MedAvail make? MedAvail (NASDAQ:MDVL) has a market capitalization of $22.54 million and generates $43.11 million in revenue each year. The company earns $-47,620,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. How many employees does MedAvail have? The company employs 287 workers across the globe. How can I contact MedAvail? MedAvail's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The official website for the company is www.medavail.com. The company can be reached via phone at (905) 812-0023, via email at jgoodford@myoscorp.com, or via fax at 973-348-5707. This page (NASDAQ:MDVL) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MedAvail Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.